BEVRA H. HAHN, M.D.; OWEN S. KANTOR, M.D.; C. KIRK OSTERLAND, M.D.
HAHN BH, KANTOR OS, OSTERLAND CK. Azathioprine plus Prednisone Compared with Prednisone Alone in the Treatment of Systemic Lupus Erythematosus: Report of a Prospective Controlled Trial in 24 Patients. Ann Intern Med. 1975;83:597-605. doi: 10.7326/0003-4819-83-5-597
Download citation file:
Published: Ann Intern Med. 1975;83(5):597-605.
A prospective, randomized drug trial compared prednisone (60 mg per day initially) to azathioprine (3 to 4 mg/kg of body weight · day initially) plus prednisone in 24 patients with life-threatening systemic lupus erythematosus. Each group contained patients matched for age, sex, disease duration, previous therapy, and clinical and laboratory features of lupus erythematosus. During a mean follow-up period of 18 to 24 months, there were no significant differences between the two groups in number of deaths, renal or extrarenal manifestations of disease, serum complement levels, DNA antibodies, antinuclear antibody titers, lupus erythematosus cells, or Coombs' antibodies. There was no convincing evidence of a steroid-sparing effect of azathioprine. Side effects attributable to steroids were equally common in both groups; infections were not increased in the combination therapy group. Azathioprine was hepatotoxic in doses of 200 mg daily or more. Azathioprine was not a useful adjunct to corticosteroids in short-term therapy of a small number of patients with severe systemic lupus.
Learn more about subscription options.
Register Now for a free account.
Lupus Erythematosus, Rheumatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only